P4M01-SIBO

P4M01-SIBO is a preclinical-stage synthetic antimicrobial peptide-based therapy being developed by P4 Microbiome, a subsidiary of D&D Pharmatech, for the treatment of Small Intestinal Bacterial Overgrowth (SIBO) and potentially Irritable Bowel Syndrome (IBS). The active ingredient is KSL-W, a synthetic decapeptide (KKVVFWVKFK) originally developed by the US Army Dental and Trauma Research Detachment. KSL-W acts by physically disrupting bacterial cell membranes, leading to rapid cell lysis and the correction of underlying dysbiosis. Unlike conventional antibiotics, KSL-W is designed to selectively target pathogenic bacteria while maintaining healthy microflora, and it rapidly degrades in the stomach to minimize systemic exposure and prevent harm to the colonic microbiome.

Other names

KKVVFWVKFKKSL decapeptide L-tryptophan analog